Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Oxycodone and PF614 with Nafamostat (MPAR-101)
NCT05090280Phase 1Completed
- Sponsor
- Ensysce Biosciences
- Start
- Dec 2021
- Primary completion
- Apr 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PF614 in pain (2 arms), sponsored by Ensysce Biosciences. Primary endpoints: Time to Maximum Plasma Concentration at 48 hours, Maximum Plasma Concentration at 48 hours and 4 more. Started Dec 2021; status: completed.
02
Drugs
PF614
03
Conditions
pain
Beyond the preview
Go deeper on NCT05090280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05090280.